Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE CYSTO versus LIPIODOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE CYSTO versus LIPIODOL.
HYPAQUE-CYSTO vs LIPIODOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HYPAQUE-CYSTO (diatrizoate meglumine) is a radiopaque contrast agent that absorbs x-rays, providing contrast in radiographic imaging. It acts as an iodinated contrast medium.
Lipiodol is an iodinated ethyl ester of the fatty acids of poppyseed oil. It acts as a radiopaque contrast agent for imaging due to its iodine content, and in chemoembolization, it selectively accumulates in hepatocellular carcinoma (HCC) via tumor neovasculature and is retained due to lack of lymphatic drainage, allowing targeted delivery of chemotherapeutic agents.
Intravesical instillation: 100-300 mL of 30% solution for retrograde cystourethrography; single administration.
Lymphangiography: 5-20 mL injected slowly into lymphatic vessels. Uterine/Fallopian tube imaging: 3-20 mL injected through cervix. Hepatic chemoembolization: 5-15 mL mixed with chemotherapeutic agents injected into hepatic artery.
None Documented
None Documented
Terminal elimination half-life: 1.5–2.5 hours (normal renal function). Prolonged in renal impairment.
Terminal elimination half-life is approximately 50-60 days, reflecting slow clearance from lipid-rich tissues.
Renal excretion via glomerular filtration: >95% unchanged within 24 hours. Fecal excretion: <5%.
Primarily eliminated via biliary/fecal route as unchanged drug; less than 1% excreted renally.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent